The therapeutic journey of biologic agents: There will be an end?

Pharmacological Research

Volumn 147, Issue , 2019, Pages

  Atzeni, Fabiola ^a   Sarzi Puttini, Piercarlo ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biosimilar; Cytokine; DMARDs

Indexed keywords

BELIMUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CYCLOPHOSPHAMIDE; METHOTREXATE; RITUXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

CLINICAL DISEASE ACTIVITY INDEX; COMORBIDITY; DAS28; DISEASE REGISTRY; DISEASE SEVERITY; DRUG APPROVAL; EDITORIAL; HUMAN; INFECTION RISK; LUPUS ERYTHEMATOSUS NEPHRITIS; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; RHEUMATIC DISEASE;

ANTIRHEUMATIC AGENTS; BIOLOGICAL FACTORS; HUMANS; RHEUMATIC DISEASES;

EID: 85069665767     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2019.104340     Document Type: Editorial

References (6)

1. Smolen, J.S., Aletaha, D., McInnes, I.B., Rheumatoid arthritis. Lancet 388:10055 (2016), 2023–2038.
2. Smolen, J.S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76:6 (2017), 960–977.
3. van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76:6 (2017), 978–991.
4. Atzeni, F., Masala, I.F., di Franco, M., Sarzi-Puttini, P., Infections in rheumatoid arthritis. Curr. Opin. Rheumatol. 29:4 (2017), 323–330.
5. Tunnicliffe, D.J., Singh-Grewal, D., Kim, S., Craig, J.C., Tong, A., Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res. (Hoboken) 67:10 (2015), 1440–1452.
6. Schulze-Koops, H., Skapenko, A., Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatology (Oxf.) 56:Suppl_4 (2017), iv30–iv48.